<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194515</url>
  </required_header>
  <id_info>
    <org_study_id>201901022A3C601</org_study_id>
    <nct_id>NCT04194515</nct_id>
  </id_info>
  <brief_title>Gut Microbiota and Bile Acids in Type 2 Diabetes Mellitus</brief_title>
  <official_title>Gut Microbiota and Bile Acids Mediate the Clinical Benefits of Metformin and YH1 in Patients With Treatment-naïve Type 2 Diabetes Mellitus: A Pilot Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will evaluate the stool microbiota, serum and fecal bile acid composition,
      and changes in blood glucose and lipid profile before and after one month of metformin or YH1
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>bile acid profile</measure>
    <time_frame>one month</time_frame>
    <description>before and after YH1 or metformin treatment</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Metformin</condition>
  <condition>YH1</condition>
  <arm_group>
    <arm_group_label>YH1 group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH1</intervention_name>
    <description>YH1 treatment for one month</description>
    <arm_group_label>YH1 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>metformin treatment for one month</description>
    <arm_group_label>Metformin group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients and treatment-naïve male patients with type 2 diabetes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Treatment-naïve male patients with type 2 diabetes;

          2. Aged 20-65 years;

          3. Body mass index (BMI) ≥ 24 kg/m2; 4.7 % ≤ glycated hemoglobin (HbA1c) &lt; 9 %;

        5.Low-density cholesterol (LDL-C) ≥ 130 mg/dl; 6.Expected to receive metformin 500 mg tid
        or YH1 6g tid for one month

        Exclusion Criteria:

          1. type 1,or other specific types of diabetes;

          2. female;

          3. history of oral hypoglycemic agents (OHAs) treatment or insulin therapy;

          4. use of lipid-lowering drugs within the past six months;

          5. serious gastrointestinal (GI) tract diseases, including peptic ulcers and GI tract
             bleeding;

          6. hepatic insufficiency with ALT &gt;72 U/L or renal insufficiency with an eGFR &lt; 60
             mL/min/1.73 m2;

          7. history of stressful situations, including diabetic ketoacidosis, nonketotic
             hyperosmolar diabetic coma, infectious disease, or surgery in the previous month;

          8. mental illness;

          9. current smoking status, alcohol or drug abuse;

         10. hemoglobin disease or chronic anemia;

         11. underlying conditions that could lead to poor compliance;

         12. severe organic diseases, including cancer, coronary heart disease, myocardial
             infarction or cerebrovascular disease;

         13. continuous antibiotic or probiotics use for over 3 days within 3 months prior to
             enrollment;

         14. continuous use of weight loss drug for over 1 month;

         15. history of YH1 therapy, or Chinese medicine treatment within the past one month.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yueh-Hsiang Huang, MD</last_name>
    <phone>+886975360240</phone>
    <email>igighuang@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yueh-Hsiang Huang, MD</last_name>
      <phone>886975360240</phone>
      <email>igighuang@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bile acid</keyword>
  <keyword>Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

